Avis de sécurité sur les produits de santé
Avis de sécurité sur les produits de santé au Canada et d’autres pays.
Pays
* Les informations sont disponibles en anglais seulement.
⇡ Canada
Santé Canada – Rappels et avis de sécurité pour le public
Autres ressources
- InfoVigilance sur les produits de santé
- Quoi de neuf – MedEffet Canada
- Bulletins de l’ISMP Canada
- Médicaments sécuritaires (en anglais seulement)
- Registre des médicaments et des produits de santé
- Signaler un effet secondaire
- Capsules Rx – Avis de Santé Canada (connection requise)
⇡ États-Unis
MedWatch Safety Alerts (human medical products):
⇡ France
⇡ Royaume-Uni
- Tofacitinib should not be used in patients older than 65 years of age, people who are current or past smokers, or individuals with other cardiovascular (such as diabetes or coronary artery disease) or malignancy risk factors…
- The paediatric indication for chloral hydrate (for children aged 2 years and older) and cloral (previously chloral) betaine (children aged 12 years and older) has been restricted to short-term treatment (maximum 2 weeks) of …
- Our sixth annual #MedSafetyWeek social media campaign will take place on 1 to 7 November 2021. This year’s theme is on the importance of reporting suspected adverse reactions to vaccines. Show your support by sharing MHRA …
- Recent information relating to COVID-19 vaccines and medicines that has been published since the September 2021 issue of Drug Safety Update, up to 1 October 2021.
- A summary of recent letters, medicine recalls and notifications sent to healthcare professionals.
- Rarely, severe adverse effects can occur on stopping treatment with topical corticosteroids, often after long-term continuous or inappropriate use of moderate to high potency products. To reduce the risks of these events, pr…
- Recent information relating to COVID-19 vaccines and medicines that has been published since the August 2021 issue of Drug Safety Update, up to 9 September 2021.
- A summary of recent letters, medicine recalls and notifications sent to healthcare professionals
- Recent information relating to COVID-19 vaccines that has been published since the July 2021 issue of Drug Safety Update.
- A summary of recent letters, medicine recalls and notifications sent to healthcare professionals
⇡ Australie
- Pentosan polysulfate sodium and pigmentary maculopathy11 October 2021 Health professionals are advised that the Product Information for pentosan polysulfate sodium has been updated with a warning about potential pigmentary maculopathy, especially after long-term use.
- Erenumab and hypertension9 September 2021 Health professionals are advised that the Product Information (PI) for erenumab has been updated with a warning statement about a potential causal relationship between the drug and hypertension.
- Propylthiouracil and carbimazole – use in pregnancy15 September 2021 Health professionals are advised that the pregnancy category for both propylthiouracil and carbimazole is being changed from category C to category D.
- Minocycline and agranulocytosis30 August 2021 Health professionals are advised that the Product Information (PI) for minocycline is in the process of being updated to include information about agranulocytosis, a rare but potentially life-threatening adverse event.
- Parenteral iron products and foetal bradycardia/Kounis syndrome26 July 2021 There are four parenteral iron products marketed in Australia. They are ferric carboxymaltose, iron polymaltose, ferric derisomaltose and iron sucrose.
- Nifedipine and pulmonary oedema when used in pregnancy26 July 2021 The Product Information for nifedipine has been updated to provide new information about the risk of acute pulmonary oedema when used as a tocolytic agent (inhibiting myometrial smooth muscle contractions) for the treatment of preterm labor in pregnancy.
- Ocrelizumab and late onset neutropenia26 July 2021 The Product Information for ocrelizumab has been updated to include a warning and further information about late onset neutropenia.
- Methylphenidate – use in pregnancy22 July 2021 Health professionals are advised that the Product Information (PI) documents for methylphenidate products have been updated with new information about use in pregnancy.
- Bupropion and serotonin syndrome2 July 2021 Health professionals are advised that the Product Information (PI) documents for bupropion-containing products have been updated to include a warning about the risk of serotonin syndrome when this drug is co-administered with other drugs known to be associated with serotonin syndrome, including selective serotonin reuptake inhibitors (SSRIs) and serotonin […]
- Updated contraception advice for tamoxifen23 June 2021 The recommended duration of contraception after finishing tamoxifen treatment has been extended from two months to nine months. This means women should continue their contraception and not become pregnant for at least nine months after tamoxifen therapy has ended.
⇡ Nouvelle-Zélande
- Risks of importing or prescribing ivermectin for prevention or treatment of COVID-19
- Dihydrocodeine: review of risks and benefits
- Myocarditis and pericarditis – rare adverse reactions to Comirnaty (Pfizer COVID-19 vaccine)
- Myocarditis – a potential adverse reaction to Comirnaty (Pfizer COVID-19 vaccine)
- Pregabalin and the possible risk of bullous dermatitis and exfoliating skin reactions
- Fluad Quad – a newly funded influenza vaccine for people aged 65 years and older
- COVID-19 vaccines and rare cases of blood clots with bleeding: no current risk with Comirnarty (Pfizer/ BioNTech) vaccine
- UPDATE: Possible risk of psoriasis exacerbation with bupropion
- UPDATE: Concern reported with the use of NovoRapid®Penfill® (insulin aspart; 3 mL cartridge) by type 1 diabetes patients
- UPDATE – Rocuronium bromide solution for injection 10mg/mL, Hameln, and reports of lack of efficacy
